| __timestamp | ImmunityBio, Inc. | Protagonist Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 1595000 | 7459000 |
| Thursday, January 1, 2015 | 11434000 | 11831000 |
| Friday, January 1, 2016 | 26546000 | 25705000 |
| Sunday, January 1, 2017 | 39778000 | 46181000 |
| Monday, January 1, 2018 | 53418000 | 59497000 |
| Tuesday, January 1, 2019 | 111997000 | 65003000 |
| Wednesday, January 1, 2020 | 139507000 | 74506000 |
| Friday, January 1, 2021 | 195958000 | 126006000 |
| Saturday, January 1, 2022 | 248149000 | 126215000 |
| Sunday, January 1, 2023 | 232366000 | 120161000 |
Unveiling the hidden dimensions of data
In the competitive world of biotechnology, innovation is the lifeblood of success. ImmunityBio, Inc. and Protagonist Therapeutics, Inc. have been at the forefront of this race, investing heavily in research and development (R&D) over the past decade. From 2014 to 2023, ImmunityBio has consistently outpaced Protagonist Therapeutics in R&D spending, with a peak investment of approximately $248 million in 2022. This represents a staggering 1,500% increase from their 2014 expenditure. Meanwhile, Protagonist Therapeutics has also shown a commendable growth trajectory, with their R&D expenses rising by over 1,500% during the same period, reaching around $126 million in 2022. These investments underscore the companies' commitment to pioneering new treatments and therapies, highlighting the critical role of R&D in driving innovation and maintaining a competitive edge in the biotech industry.
R&D Insights: How Eli Lilly and Company and Protagonist Therapeutics, Inc. Allocate Funds
Research and Development Expenses Breakdown: BeiGene, Ltd. vs ImmunityBio, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Ascendis Pharma A/S and ImmunityBio, Inc.
Research and Development: Comparing Key Metrics for Jazz Pharmaceuticals plc and ImmunityBio, Inc.
R&D Insights: How Madrigal Pharmaceuticals, Inc. and ImmunityBio, Inc. Allocate Funds
Who Prioritizes Innovation? R&D Spending Compared for Verona Pharma plc and ImmunityBio, Inc.
Research and Development Investment: ADMA Biologics, Inc. vs Protagonist Therapeutics, Inc.
R&D Insights: How CymaBay Therapeutics, Inc. and Protagonist Therapeutics, Inc. Allocate Funds
Who Prioritizes Innovation? R&D Spending Compared for Apellis Pharmaceuticals, Inc. and Protagonist Therapeutics, Inc.
Analyzing R&D Budgets: Perrigo Company plc vs Protagonist Therapeutics, Inc.
Research and Development Investment: Arrowhead Pharmaceuticals, Inc. vs ImmunityBio, Inc.
R&D Spending Showdown: Protagonist Therapeutics, Inc. vs Xencor, Inc.